Step 1. Identify whether you want a cell line to grow in tissue culture, or one to grow in the brain of a mouse.
Step 2. Put your intended cell lines in the cart and press “place order” this provides a quote for your company and reserves the stock for you.
Step 3. We email you a confirmation and will send any information your company needs to set us up as vendors etc.
Step 4. We send the vials, payment upon arrival.
YOU DO NOT PROVIDE ANY PAYMENT INFORMATION ON THIS SITE, YOU CAN NOT GET YOUR CELLS UNTIL YOU HAVE PROCESSED AN ORDER HERE.
Why? Because the terms and conditions serves as the MTA between the Hutch and you. Until that is done, no vials leave the Hutch.
Please call me before you start surgeries so that we can chat about the process, the methods paper hasn’t been published and I am often contacted months later with problems/questions about tumor onset that could have been avoided with a simple phone call. We are a small community and I don’t mind! People have even flown down to our lab to watch and I love helping and sharing which is much easier to do before there is a problem! I am the person who manages this website and the orders, who processes the cells, does the surgeries and creates the vials you are buying. I want to make sure you are successful!
In the late 1990s, when Dr. Olson’s laboratory was beginning, the Washington Women’s Foundation provided a grant that enabled our laboratory to serve as a National Brain Tumor Resource Laboratory (BTRL). Our BTRL generated resources from patient surgical samples and made panels that could be shared freely with any investigator around the world. We established practices that reduced barriers to collaboration and promoted advanced molecular studies that led to the incredible understanding of pediatric brain tumor biology that has evolved in the subsequent decade. With continued support from Seattle Children’s Hospital Guilds, we expanded services to the generation and sharing of mouse medulloblastoma models. Our models are now used in over 50 labs world-wide and provided the scientific basis for four national clinical trials, and these resources are available to the international research community because of the generous support of the Run of Hope www.runofhopeseattle.org
In 2009, a generous gift launched a new program focused on generating patient-specific cell lines for drug screening and mouse models for drug prioritization. We challenged our team to imagine the day when a surgical sample from a child could generate cell lines and mice that would rapidly generate data that could guide clinical decisions for that particular patient. Prior to achieving this goal, we reasoned that the data generated with these resources could shape the next generation of national clinical trials.
We have now generated models for rare and under-studied types of pediatric brain cancer. Since 2009, the Olson Laboratory generated over 30 new mouse models that carry human brain tumors derived from our patient’s surgical specimens. The same specimens are used to generate patient-derived cell lines that are useful for drug screening and prioritization. About half the patient samples come from Seattle Children’s Hospital and the remainder from Children’s Oncology Group sites across America. Because of the generosity of donors, we are able to share these resources with any academic laboratory around the world that wishes to study pediatric brain tumors. The fee for each mouse model supports ongoing costs of maintaining this program. Please contact us if the fee creates a barrier.
All of the mouse models are being molecularly defined. This data will be added to the website following curation. Please contact us for draft data in the meantime. The goal of genomic characterization is that future therapies can be directed specifically toward the children who are likely to benefit – and so that children who are unlikely to benefit from a treatment are spared exposure to it and treated with more promising agents. We offer the mouse models before genomic profiling is complete because we wish to accelerate research and minimize barriers.